Abstract
1 The efficacy and safety of doxazosin and atenolol were compared following once-daily administration for up to 1 year, with a minimum of 20 weeks' active treatment.
2 According to response, patients received doxazosin 1-16 mg day-1 or atenolol 50-100 mg day-1. Mean daily doses at the final efficacy assessment (between 20 weeks and 1 year) were doxazosin 11.8 mg and atenolol 94.2 mg.
3 Atenolol produced somewhat greater falls in blood pressure than doxazosin. The differences were statistically significant in the supine but not in the standing position. A small mean reduction in heart rate was produced by doxazosin whereas atenolol produced a marked bradycardia. Analysis of the same patient group at 20 weeks revealed similar overall profiles of activity except that atenolol produced greater falls in blood pressure than in the longer term analysis.
4 Serum concentrations of HDL/total cholesterol ratio were raised in the doxazosin treatment group and lowered in the atenolol group. Triglyceride concentrations fell in the doxazosin group and rose in the atenolol group. Significant differences (P < 0.001) were observed between treatment groups for these parameters, all differences being in favour of doxazosin.
5 Pharmacokinetics of doxazosin, measured at steady state in 36 patients, showed dose-related plasma concentrations, a mean half-life of about 12 h and relatively low intersubject variation.
6 The incidence of side-effects was slightly greater for patients in the doxazosin group. Drug-related side-effects were mostly mild to moderate in severity with no serious drug-related occurrences in either treatment group.
7 No serious drug-related abnormalities in laboratory biochemistry and haematology tests were observed in either treatment group.
Keywords: atenolol, blood pressure, doxazosin, lipids, pharmacokinetics
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Elliott H. L., Meredith P. A., Sumner D. J., McLean K., Reid J. L. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol. 1982 May;13(5):699–703. doi: 10.1111/j.1365-2125.1982.tb01439.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lehtonen A., Himanen P., Saraste M., Niittymäki K., Marniemi J. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol. 1986;21 (Suppl 1):77S–81S. doi: 10.1111/j.1365-2125.1986.tb02857.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller G. J. High density lipoproteins and atherosclerosis. Annu Rev Med. 1980;31:97–108. doi: 10.1146/annurev.me.31.020180.000525. [DOI] [PubMed] [Google Scholar]
- Miller N. E. Plasma lipoproteins, antihypertensive drugs and coronary heart disease. J Cardiovasc Pharmacol. 1985;7 (Suppl 2):S105–S109. doi: 10.1097/00005344-198507002-00020. [DOI] [PubMed] [Google Scholar]
- Rubin P. C., Brunton J., Meredith P. Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection. J Chromatogr. 1980 Nov 14;221(1):193–195. doi: 10.1016/s0378-4347(00)81025-7. [DOI] [PubMed] [Google Scholar]
- Timmermans P. B., Kwa H. Y., Ali F. K., van Zwieten P. A. Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities. Arch Int Pharmacodyn Ther. 1980 Jun;245(2):218–235. [PubMed] [Google Scholar]
- Vincent J., Elliott H. L., Meredith P. A., Reid J. L. Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol. 1983 Jun;15(6):719–725. doi: 10.1111/j.1365-2125.1983.tb01556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinberger M. H. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med. 1985 Jun;145(6):1102–1105. [PubMed] [Google Scholar]
- de Leeuw P. W., Ligthart J. J., Smout A. J., Birkenhäger W. H. Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist. Eur J Clin Pharmacol. 1982;23(5):397–401. doi: 10.1007/BF00605988. [DOI] [PubMed] [Google Scholar]